A  ||| S:0 E:2 ||| DT
CASE  ||| S:2 E:7 ||| NN
OF  ||| S:7 E:10 ||| IN
ADVANCED  ||| S:10 E:19 ||| NNP
BLADDER  ||| S:19 E:27 ||| NNP
NEUROENDOCRINE  ||| S:27 E:42 ||| NNP
CARCINOMA  ||| S:42 E:52 ||| NNP
( ||| S:52 E:53 ||| -LRB-
SMALL  ||| S:53 E:59 ||| NNP
CELL  ||| S:59 E:64 ||| NNP
CARCINOMA ||| S:64 E:73 ||| NNP
)  ||| S:73 E:75 ||| -RRB-
SIGNIFICANTLY  ||| S:75 E:89 ||| NNP
IMPROVED  ||| S:89 E:98 ||| NNP
BY  ||| S:98 E:101 ||| NNP
LOW  ||| S:101 E:105 ||| NNP
DOSE  ||| S:105 E:110 ||| NNP
OF  ||| S:110 E:113 ||| IN
ORAL  ||| S:113 E:118 ||| NNP
TEGAFUR-URACIL  ||| S:118 E:133 ||| NNP
A  ||| S:133 E:135 ||| NNP
81-old-woman  ||| S:135 E:148 ||| NNP
underwent  ||| S:148 E:158 ||| VBD
a  ||| S:158 E:160 ||| DT
transurethral  ||| S:160 E:174 ||| JJ
resection  ||| S:174 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
bladder  ||| S:187 E:195 ||| JJ
tumor  ||| S:195 E:201 ||| NN
( ||| S:201 E:202 ||| -LRB-
TURBT ||| S:202 E:207 ||| NNP
)  ||| S:207 E:209 ||| -RRB-
at  ||| S:209 E:212 ||| IN
a  ||| S:212 E:214 ||| DT
nearby  ||| S:214 E:221 ||| JJ
hospital  ||| S:221 E:230 ||| NN
in  ||| S:230 E:233 ||| IN
April  ||| S:233 E:239 ||| NNP
2011 ||| S:239 E:243 ||| CD
.  ||| S:243 E:245 ||| .
The  ||| S:245 E:249 ||| DT
diagnosis  ||| S:249 E:259 ||| NN
was  ||| S:259 E:263 ||| VBD
invasive  ||| S:263 E:272 ||| JJ
urothelial  ||| S:272 E:283 ||| JJ
carcinoma ||| S:283 E:292 ||| NN
,  ||| S:292 E:294 ||| ,
G3  ||| S:294 E:297 ||| NNP
with  ||| S:297 E:302 ||| IN
a  ||| S:302 E:304 ||| DT
component  ||| S:304 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
bladder  ||| S:317 E:325 ||| JJ
small  ||| S:325 E:331 ||| JJ
cell  ||| S:331 E:336 ||| NN
carcinoma ||| S:336 E:345 ||| NN
,  ||| S:345 E:347 ||| ,
T1  ||| S:347 E:350 ||| NNP
or  ||| S:350 E:353 ||| CC
more ||| S:353 E:357 ||| JJR
.  ||| S:357 E:359 ||| .
She  ||| S:359 E:363 ||| PRP
was  ||| S:363 E:367 ||| VBD
recommended  ||| S:367 E:379 ||| VBN
to  ||| S:379 E:382 ||| TO
visit  ||| S:382 E:388 ||| VB
our  ||| S:388 E:392 ||| PRP$
hospital  ||| S:392 E:401 ||| NN
for  ||| S:401 E:405 ||| IN
combined  ||| S:405 E:414 ||| JJ
modality  ||| S:414 E:423 ||| JJ
therapy  ||| S:423 E:431 ||| NN
of  ||| S:431 E:434 ||| IN
bladder  ||| S:434 E:442 ||| JJ
cancer ||| S:442 E:448 ||| NN
,  ||| S:448 E:450 ||| ,
but  ||| S:450 E:454 ||| CC
she  ||| S:454 E:458 ||| PRP
refused  ||| S:458 E:466 ||| VBD
the  ||| S:466 E:470 ||| DT
treatment  ||| S:470 E:480 ||| NN
for  ||| S:480 E:484 ||| IN
over  ||| S:484 E:489 ||| IN
one  ||| S:489 E:493 ||| CD
year ||| S:493 E:497 ||| NN
.  ||| S:497 E:499 ||| .
In  ||| S:499 E:502 ||| IN
May  ||| S:502 E:506 ||| NNP
2012 ||| S:506 E:510 ||| CD
,  ||| S:510 E:512 ||| ,
she  ||| S:512 E:516 ||| PRP
came  ||| S:516 E:521 ||| VBD
to  ||| S:521 E:524 ||| TO
our  ||| S:524 E:528 ||| PRP$
hospital  ||| S:528 E:537 ||| NN
with  ||| S:537 E:542 ||| IN
the  ||| S:542 E:546 ||| DT
chief  ||| S:546 E:552 ||| JJ
complaint  ||| S:552 E:562 ||| NN
of  ||| S:562 E:565 ||| IN
pain  ||| S:565 E:570 ||| NN
at  ||| S:570 E:573 ||| IN
urination ||| S:573 E:582 ||| NN
.  ||| S:582 E:584 ||| .
Cystoscopy  ||| S:584 E:595 ||| NNP
revealed  ||| S:595 E:604 ||| VBD
non-papillary  ||| S:604 E:618 ||| JJ
sessile  ||| S:618 E:626 ||| JJ
tumor  ||| S:626 E:632 ||| NN
in  ||| S:632 E:635 ||| IN
the  ||| S:635 E:639 ||| DT
top  ||| S:639 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
bladder ||| S:650 E:657 ||| NN
,  ||| S:657 E:659 ||| ,
and  ||| S:659 E:663 ||| CC
CT  ||| S:663 E:666 ||| NNP
scan  ||| S:666 E:671 ||| VBD
demonstrated  ||| S:671 E:684 ||| VBN
the  ||| S:684 E:688 ||| DT
presence  ||| S:688 E:697 ||| NN
of  ||| S:697 E:700 ||| IN
the  ||| S:700 E:704 ||| DT
right  ||| S:704 E:710 ||| JJ
obturator  ||| S:710 E:720 ||| JJ
lymph  ||| S:720 E:726 ||| NNS
nodes  ||| S:726 E:732 ||| VBP
swollen  ||| S:732 E:740 ||| VBN
up  ||| S:740 E:743 ||| RP
to  ||| S:743 E:746 ||| TO
1.2  ||| S:746 E:750 ||| CD
cm  ||| S:750 E:753 ||| NN
in  ||| S:753 E:756 ||| IN
size ||| S:756 E:760 ||| NN
.  ||| S:760 E:762 ||| .
The  ||| S:762 E:766 ||| DT
second  ||| S:766 E:773 ||| JJ
TURBT  ||| S:773 E:779 ||| NNP
was  ||| S:779 E:783 ||| VBD
performed  ||| S:783 E:793 ||| VBN
and  ||| S:793 E:797 ||| CC
the  ||| S:797 E:801 ||| DT
diagnosis  ||| S:801 E:811 ||| NN
was  ||| S:811 E:815 ||| VBD
bladder  ||| S:815 E:823 ||| JJ
small  ||| S:823 E:829 ||| JJ
cell  ||| S:829 E:834 ||| NN
carcinoma  ||| S:834 E:844 ||| NNS
( ||| S:844 E:845 ||| -LRB-
pT3N2M0 ||| S:845 E:852 ||| NNP
)  ||| S:852 E:854 ||| -RRB-
according  ||| S:854 E:864 ||| VBG
to  ||| S:864 E:867 ||| TO
urothelial  ||| S:867 E:878 ||| VB
cancer  ||| S:878 E:885 ||| NN
guidelines  ||| S:885 E:896 ||| NNS
of  ||| S:896 E:899 ||| IN
the  ||| S:899 E:903 ||| DT
Japanese  ||| S:903 E:912 ||| JJ
Urological  ||| S:912 E:923 ||| NNP
Association  ||| S:923 E:935 ||| NNP
( ||| S:935 E:936 ||| -LRB-
JUA ||| S:936 E:939 ||| NNP
) ||| S:939 E:940 ||| -RRB-
.  ||| S:940 E:942 ||| .
Because  ||| S:942 E:950 ||| IN
she  ||| S:950 E:954 ||| PRP
strongly  ||| S:954 E:963 ||| RB
refused  ||| S:963 E:971 ||| VBD
hospitalization  ||| S:971 E:987 ||| VBN
anymore ||| S:987 E:994 ||| RB
,  ||| S:994 E:996 ||| ,
we  ||| S:996 E:999 ||| PRP
started  ||| S:999 E:1007 ||| VBD
daily  ||| S:1007 E:1013 ||| JJ
oral  ||| S:1013 E:1018 ||| JJ
intake  ||| S:1018 E:1025 ||| NN
of  ||| S:1025 E:1028 ||| IN
low  ||| S:1028 E:1032 ||| JJ
dose  ||| S:1032 E:1037 ||| NN
Tegafur-Uracil  ||| S:1037 E:1052 ||| NNS
( ||| S:1052 E:1053 ||| -LRB-
100  ||| S:1053 E:1057 ||| CD
mg ||| S:1057 E:1059 ||| CD
)  ||| S:1059 E:1061 ||| -RRB-
for  ||| S:1061 E:1065 ||| IN
the  ||| S:1065 E:1069 ||| DT
treatment ||| S:1069 E:1078 ||| NN
.  ||| S:1078 E:1080 ||| .
After  ||| S:1080 E:1086 ||| IN
one  ||| S:1086 E:1090 ||| CD
month ||| S:1090 E:1095 ||| NN
,  ||| S:1095 E:1097 ||| ,
the  ||| S:1097 E:1101 ||| DT
serum  ||| S:1101 E:1107 ||| JJ
Neuron-Specific  ||| S:1107 E:1123 ||| JJ
Enolase  ||| S:1123 E:1131 ||| NNP
( ||| S:1131 E:1132 ||| -LRB-
NSE ||| S:1132 E:1135 ||| NNP
;  ||| S:1135 E:1137 ||| :
tumor  ||| S:1137 E:1143 ||| NN
maker  ||| S:1143 E:1149 ||| NN
of  ||| S:1149 E:1152 ||| IN
small  ||| S:1152 E:1158 ||| JJ
cell  ||| S:1158 E:1163 ||| NN
cancer ||| S:1163 E:1169 ||| NN
)  ||| S:1169 E:1171 ||| -RRB-
level  ||| S:1171 E:1177 ||| NN
was  ||| S:1177 E:1181 ||| VBD
elevated  ||| S:1181 E:1190 ||| VBN
to  ||| S:1190 E:1193 ||| TO
27.6  ||| S:1193 E:1198 ||| CD
ng ||| S:1198 E:1200 ||| CD
/ ||| S:1200 E:1201 ||| CD
ml  ||| S:1201 E:1204 ||| NNS
and  ||| S:1204 E:1208 ||| CC
the  ||| S:1208 E:1212 ||| DT
right  ||| S:1212 E:1218 ||| JJ
obturator  ||| S:1218 E:1228 ||| JJ
lymph  ||| S:1228 E:1234 ||| NN
node  ||| S:1234 E:1239 ||| NNS
was  ||| S:1239 E:1243 ||| VBD
enlarged  ||| S:1243 E:1252 ||| VBN
up  ||| S:1252 E:1255 ||| RP
to  ||| S:1255 E:1258 ||| TO
1.9  ||| S:1258 E:1262 ||| CD
cm ||| S:1262 E:1264 ||| NNS
.  ||| S:1264 E:1266 ||| .
Therefore ||| S:1266 E:1275 ||| RB
,  ||| S:1275 E:1277 ||| ,
the  ||| S:1277 E:1281 ||| DT
Trgafur-Uracil  ||| S:1281 E:1296 ||| JJ
dose  ||| S:1296 E:1301 ||| NN
was  ||| S:1301 E:1305 ||| VBD
increased  ||| S:1305 E:1315 ||| VBN
to  ||| S:1315 E:1318 ||| TO
200  ||| S:1318 E:1322 ||| CD
mg  ||| S:1322 E:1325 ||| CD
daily ||| S:1325 E:1330 ||| JJ
.  ||| S:1330 E:1332 ||| .
After  ||| S:1332 E:1338 ||| IN
then ||| S:1338 E:1342 ||| RB
,  ||| S:1342 E:1344 ||| ,
the  ||| S:1344 E:1348 ||| DT
serum  ||| S:1348 E:1354 ||| JJ
NSE  ||| S:1354 E:1358 ||| NNP
level  ||| S:1358 E:1364 ||| NN
was  ||| S:1364 E:1368 ||| VBD
decreased  ||| S:1368 E:1378 ||| VBN
to  ||| S:1378 E:1381 ||| TO
15.5  ||| S:1381 E:1386 ||| CD
ng ||| S:1386 E:1388 ||| CD
/ ||| S:1388 E:1389 ||| CD
ml  ||| S:1389 E:1392 ||| NNS
following  ||| S:1392 E:1402 ||| VBG
reduction  ||| S:1402 E:1412 ||| NN
in  ||| S:1412 E:1415 ||| IN
size  ||| S:1415 E:1420 ||| NN
of  ||| S:1420 E:1423 ||| IN
the  ||| S:1423 E:1427 ||| DT
obturator  ||| S:1427 E:1437 ||| JJ
lymph  ||| S:1437 E:1443 ||| JJ
nodes  ||| S:1443 E:1449 ||| NN
with  ||| S:1449 E:1454 ||| IN
partial  ||| S:1454 E:1462 ||| JJ
response  ||| S:1462 E:1471 ||| NN
in  ||| S:1471 E:1474 ||| IN
December  ||| S:1474 E:1483 ||| NNP
2013 ||| S:1483 E:1487 ||| CD
.  ||| S:1487 E:1489 ||| .
After  ||| S:1489 E:1495 ||| IN
two  ||| S:1495 E:1499 ||| CD
years  ||| S:1499 E:1505 ||| NNS
of  ||| S:1505 E:1508 ||| IN
follow-up  ||| S:1508 E:1518 ||| JJ
period ||| S:1518 E:1524 ||| NN
,  ||| S:1524 E:1526 ||| ,
her  ||| S:1526 E:1530 ||| PRP$
regular  ||| S:1530 E:1538 ||| JJ
urine  ||| S:1538 E:1544 ||| JJ
test  ||| S:1544 E:1549 ||| NN
showed  ||| S:1549 E:1556 ||| VBD
normal  ||| S:1556 E:1563 ||| JJ
findings ||| S:1563 E:1571 ||| NNS
,  ||| S:1571 E:1573 ||| ,
and  ||| S:1573 E:1577 ||| CC
no  ||| S:1577 E:1580 ||| DT
apparent  ||| S:1580 E:1589 ||| JJ
recurrence  ||| S:1589 E:1600 ||| NN
was  ||| S:1600 E:1604 ||| VBD
detected  ||| S:1604 E:1613 ||| VBN
on  ||| S:1613 E:1616 ||| IN
urinary  ||| S:1616 E:1624 ||| JJ
bladder  ||| S:1624 E:1632 ||| NN
with  ||| S:1632 E:1637 ||| IN
MRI  ||| S:1637 E:1641 ||| NNP
and  ||| S:1641 E:1645 ||| CC
Cystoscopy ||| S:1645 E:1655 ||| NNP
.  ||| S:1655 E:1657 ||| .
This  ||| S:1657 E:1662 ||| DT
is  ||| S:1662 E:1665 ||| VBZ
a  ||| S:1665 E:1667 ||| DT
case  ||| S:1667 E:1672 ||| NN
of  ||| S:1672 E:1675 ||| IN
advanced  ||| S:1675 E:1684 ||| JJ
bladder  ||| S:1684 E:1692 ||| JJ
small  ||| S:1692 E:1698 ||| JJ
cell  ||| S:1698 E:1703 ||| NN
carcinoma  ||| S:1703 E:1713 ||| VBZ
significantly  ||| S:1713 E:1727 ||| RB
improved  ||| S:1727 E:1736 ||| VBN
by  ||| S:1736 E:1739 ||| IN
oral  ||| S:1739 E:1744 ||| JJ
administration  ||| S:1744 E:1759 ||| NN
of  ||| S:1759 E:1762 ||| IN
Tegafur-Uracil  ||| S:1762 E:1777 ||| JJ
200  ||| S:1777 E:1781 ||| CD
mg ||| S:1781 E:1783 ||| CD
/ ||| S:1783 E:1784 ||| CD
day  ||| S:1784 E:1788 ||| NN
for  ||| S:1788 E:1792 ||| IN
over  ||| S:1792 E:1797 ||| IN
2  ||| S:1797 E:1799 ||| CD
years ||| S:1799 E:1804 ||| NNS
.  ||| S:1804 E:1806 ||| .
